Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SMS-Based Active Surveillance of Adverse Events following Immunization in Children: The VigiVax Study.
Gonella LA, Moretti F, Capuano A, De Sarro C, Ferrara L, Geninatti E, Guarnieri G, Hysolakoj X, Lalli M, Leoni O, Mangano AMP, Marani Toro P, Mecchia V, Merlano MC, Palleria C, Potenza AM, Rossi P, Rossi M, Sanità F, Sapigni E, Scavone C, Sommaro C, Tuccori M, Zanoni G, Moretti U, VigiVax Working Group. Gonella LA, et al. Among authors: geninatti e. Vaccines (Basel). 2024 Sep 20;12(9):1076. doi: 10.3390/vaccines12091076. Vaccines (Basel). 2024. PMID: 39340106 Free PMC article.
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, Turitto G, Scandurra G, Petrella MC, Forestieri V, Rizzetto M, Mammoliti S, Artioli G, Cioffi R, Borsotti L, Bellero M, Rognone C, Carbone V, Ferrandina G, Mantiero M, Azzolina C, Geninatti E, Pignata S, Valabrega G. Tuninetti V, et al. Among authors: geninatti e. Eur J Cancer. 2024 May;203:114039. doi: 10.1016/j.ejca.2024.114039. Epub 2024 Mar 30. Eur J Cancer. 2024. PMID: 38598922
Italian Emergency Department Visits and Hospitalizations for Outpatients' Adverse Drug Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS Study).
Lombardi N, Crescioli G, Bettiol A, Tuccori M, Capuano A, Bonaiuti R, Mugelli A, Venegoni M, Vighi GD, Vannacci A; MEREAFaPS Study group. Lombardi N, et al. Front Pharmacol. 2020 Apr 6;11:412. doi: 10.3389/fphar.2020.00412. eCollection 2020. Front Pharmacol. 2020. PMID: 32327995 Free PMC article.